selenocysteine has been researched along with Benign Neoplasms in 38 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (2.63) | 18.2507 |
| 2000's | 7 (18.42) | 29.6817 |
| 2010's | 23 (60.53) | 24.3611 |
| 2020's | 7 (18.42) | 2.80 |
| Authors | Studies |
|---|---|
| Cao, M; Dai, Y; Pan, S; Sun, C; Tan, Y; Xu, H; Zhang, L | 1 |
| Arnér, ESJ; Cheng, Q; Gencheva, R | 1 |
| Seale, LA; Shimada, BK; Swanson, S; Toh, P | 1 |
| DeAngelo, SL; Győrffy, B; Koutmos, M; Shah, YM | 1 |
| Kai, X; Li, M; Sheng, Z; Shi, Y; Yin, X; Zhang, L; Zhang, Y | 1 |
| Carlisle, AE; Doshi, MB; Greer, PL; Joseph, AB; Kim, D; Lee, N; Li, R; Matthew-Onabanjo, AN; Park, SJ; Peppers, A; Shaw, LM; Simin, K; Smith, M; Spears, ME; Youkana, D; Zhu, LJ | 1 |
| Diamond, AM; Kadkol, S | 1 |
| Arnér, ESJ; Gencheva, R | 1 |
| Bergan, R; Burk, RF; Davis, W; George, S; Hill, KE; Marshall, JR; Payne Ondracek, R; Perloff, M; Pili, R | 1 |
| Chen, C; Du, J; Ge, C; Gu, Z; Liu, J; Wu, R; Yan, L; Yi, X; Yong, Y; Zhang, X; Zhao, Y | 1 |
| Kai, X; Xue, Y; Yin, X; Zhang, L; Zhang, Y; Zhao, J; Zheng, Y | 1 |
| Aitken, JB; Finney, L; Harris, HH; Vogt, S; Weekley, CM; Witting, PK | 1 |
| Chen, Q; Hao, X; Li, J; Liu, H; Liu, J; Liu, L; Ma, B; Mu, C; Yan, C; Yue, W; Zhao, L; Zhu, Y | 1 |
| Harris, HH; Weekley, CM | 1 |
| Barbante, C; Jitaru, P; Roman, M | 1 |
| Carlson, BA; Gladyshev, VN; Hatfield, DL; Tsuji, PA | 1 |
| Cao, S; Durrani, FA; Rustum, YM; Tóth, K | 1 |
| Alcutt, S; Artigues, A; Cooper, AJ; Dorai, T; Jones, ME; Krasnikov, BF; Li, J; Pinto, JT; Villar, MT | 1 |
| Bindoli, A; Citta, A; Folda, A; Jaouen, G; Pigeon, P; Rigobello, MP; Salmain, M; Top, S; Vessières, A | 1 |
| Begley, TJ; Begley, U; Clark, R; Dedon, PC; Dziergowska, A; Endres, L; Gu, C; Małkiewicz, A; Melendez, JA | 1 |
| Cheremushkina, IV; Varlamova, EG | 1 |
| Gangapurkar, B; Jariwalla, RJ; Nakamura, D | 1 |
| Echigo, S; Endo, M; Rikiishi, H; Shinohara, F; Suzuki, M | 1 |
| Cheng, WH; Kang, MM; Schoene, NW; Wu, M | 1 |
| Handy, DE; Loscalzo, J; Lubos, E | 1 |
| Aitken, JB; de Jonge, MD; Finney, LA; Harris, HH; Howard, DL; Musgrave, IF; Paterson, DJ; Vogt, S; Weekley, CM | 1 |
| Liu, X; Pietsch, KE; Sturla, SJ | 1 |
| Bhattacharya, A | 1 |
| Bernhard, EJ | 1 |
| Antoch, MP; Chernov, MV; Comas-Soberats, M; Fedtsova, N; Gleiberman, AS; Gudkov, AV; Hu, Y; Jackson, M; Kuropatwinski, KK; Rustum, YM; Spengler, ML | 1 |
| Burke, TR; Cui, H; Rader, C; Thomas, JD | 1 |
| Cao, S; Durrani, FA; Rustum, YM | 1 |
| Cao, S; Durrani, FA; Fakih, M; Rustum, YM | 1 |
| Rayman, MP | 1 |
| Abdulah, R; Koyama, H; Miyazaki, K; Nakazawa, M | 1 |
| Azrak, RG; Cao, S; Combs, GF; Durrani, FA; Fakih, M; Pendyala, L; Prey, J; Rustum, YM; Smith, PF | 1 |
| Ganther, HE | 2 |
18 review(s) available for selenocysteine and Benign Neoplasms
| Article | Year |
|---|---|
Thioredoxin reductase selenoproteins from different organisms as potential drug targets for treatment of human diseases.
Topics: Humans; Neoplasms; Selenocysteine; Selenoproteins; Thioredoxin-Disulfide Reductase; Tumor Microenvironment | 2022 |
Metabolism of Selenium, Selenocysteine, and Selenoproteins in Ferroptosis in Solid Tumor Cancers.
Topics: Ferroptosis; Humans; Neoplasms; Selenium; Selenocysteine; Selenoproteins | 2022 |
Selenoproteins and tRNA-Sec: regulators of cancer redox homeostasis.
Topics: Antioxidants; Homeostasis; Humans; Neoplasms; Oxidation-Reduction; RNA, Transfer; Selenium; Selenocysteine; Selenoproteins | 2023 |
The Interaction between Dietary Selenium Intake and Genetics in Determining Cancer Risk and Outcome.
Topics: 3' Untranslated Regions; Codon, Terminator; Eating; Genetic Predisposition to Disease; Humans; Neoplasms; Nutrigenomics; Protein Biosynthesis; Risk Factors; RNA, Messenger; Selenium; Selenocysteine; Selenoproteins | 2020 |
Thioredoxin Reductase Inhibition for Cancer Therapy.
Topics: Animals; Humans; Mice; Mitochondria; Neoplasms; Oxidation-Reduction; Reactive Oxygen Species; Selenocysteine; Thioredoxin Reductase 1 | 2022 |
Selenium metabolism in cancer cells: the combined application of XAS and XFM techniques to the problem of selenium speciation in biological systems.
Topics: Animals; Copper; Fluorescence; Humans; Microscopy, Fluorescence; Neoplasms; Organoselenium Compounds; Selenium; Selenocysteine; Selenomethionine; Sodium Selenite; X-Ray Absorption Spectroscopy | 2013 |
Which form is that? The importance of selenium speciation and metabolism in the prevention and treatment of disease.
Topics: Clinical Trials as Topic; Cystine; Dietary Supplements; Histone Deacetylase Inhibitors; Humans; Neoplasms; Organoselenium Compounds; Reactive Oxygen Species; Selenium Compounds; Selenocysteine; Selenomethionine; Selenoproteins; Sulfhydryl Compounds | 2013 |
Selenium biochemistry and its role for human health.
Topics: Diabetes Mellitus; Humans; Inflammation; Metabolic Networks and Pathways; Models, Biological; Neoplasms; Selenium; Selenocysteine; Selenoproteins; Trace Elements | 2014 |
Selenium and selenocysteine: roles in cancer, health, and development.
Topics: Humans; Neoplasm Proteins; Neoplasms; Selenium; Selenocysteine; Selenoproteins | 2014 |
Contribution of mammalian selenocysteine-containing proteins to carcinogenesis.
Topics: Animals; Carcinogenesis; Humans; Neoplasms; Selenium; Selenocysteine; Selenoproteins | 2017 |
Glutathione peroxidase-1 in health and disease: from molecular mechanisms to therapeutic opportunities.
Topics: Amino Acid Sequence; Animals; Cardiovascular Diseases; Cell Death; Diabetes Mellitus; Enzyme Inhibitors; Gene Expression; Gene Expression Regulation; Genetic Predisposition to Disease; Glutathione Peroxidase; Glutathione Peroxidase GPX1; Humans; Molecular Sequence Data; Neoplasms; Oxidation-Reduction; Oxidative Stress; Polymorphism, Genetic; Protein Conformation; Reactive Oxygen Species; Risk Factors; Selenocysteine | 2011 |
Methylselenocysteine: a promising antiangiogenic agent for overcoming drug delivery barriers in solid malignancies for therapeutic synergy with anticancer drugs.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Cysteine; Drug Synergism; Humans; Neoplasms; Organoselenium Compounds; Selenocysteine | 2011 |
Interventions that induce modifications in the tumor microenvironment.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antineoplastic Agents; Cell Adhesion; Cell Hypoxia; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Cysteine; Cytotoxins; Drug Screening Assays, Antitumor; Extracellular Matrix; Genetic Therapy; Humans; Immunotherapy; Molecular Targeted Therapy; Neoplasm Proteins; Neoplasms; Neoplasms, Experimental; Neoplastic Stem Cells; Neovascularization, Pathologic; Organoselenium Compounds; Radiation Tolerance; Radiotherapy; Selenocysteine; Signal Transduction; Stromal Cells; Tumor Microenvironment | 2011 |
Selenium protects against toxicity induced by anticancer drugs and augments antitumor activity: a highly selective, new, and novel approach for the treatment of solid tumors.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cysteine; Drug Synergism; Humans; Irinotecan; Mice; Neoplasms; Organoselenium Compounds; Rats; Selenocysteine; Selenomethionine | 2005 |
Selenium in cancer prevention: a review of the evidence and mechanism of action.
Topics: Anticarcinogenic Agents; Antineoplastic Agents; Apoptosis; Gene Expression Regulation, Neoplastic; Genotype; Humans; Neoplasms; Oxidation-Reduction; Selenium; Selenocysteine; Selenoproteins | 2005 |
Chemical forms of selenium for cancer prevention.
Topics: Anticarcinogenic Agents; Chromatography; Chromatography, High Pressure Liquid; Cysteine; Food; Glutathione Peroxidase; Humans; Iodide Peroxidase; Mass Spectrometry; Methionine Sulfoxide Reductases; Models, Chemical; Neoplasms; Organoselenium Compounds; Selenium; Selenocysteine; Selenoprotein P; Selenoprotein W; Thioredoxin-Disulfide Reductase | 2005 |
Selenium metabolism, selenoproteins and mechanisms of cancer prevention: complexities with thioredoxin reductase.
Topics: Animals; Anticarcinogenic Agents; Apoptosis; Cell Cycle Proteins; Cell Division; Cysteine; Enzyme Inhibitors; Gene Expression Regulation; Humans; Methylation; Mice; Molecular Weight; Neoplasms; Neoplasms, Experimental; Oxidation-Reduction; Protein Kinase C; Proteins; Selenium; Selenocysteine; Selenoproteins; Thioredoxin-Disulfide Reductase; Thioredoxins; Transcription Factors | 1999 |
Selenium metabolism and mechanisms of cancer prevention.
Topics: Anticarcinogenic Agents; Antioxidants; Humans; Neoplasms; Nutritional Requirements; Proteins; Selenium; Selenocysteine; Selenoproteins | 2001 |
1 trial(s) available for selenocysteine and Benign Neoplasms
| Article | Year |
|---|---|
Selenomethionine and methyl selenocysteine: multiple-dose pharmacokinetics in selenium-replete men.
Topics: Adult; Aged; Case-Control Studies; Chemoprevention; Dietary Supplements; Drug Monitoring; Humans; Male; Middle Aged; Neoplasms; Selenocysteine; Selenomethionine; Time Factors | 2017 |
19 other study(ies) available for selenocysteine and Benign Neoplasms
| Article | Year |
|---|---|
Copper-Selenocysteine Quantum Dots for NIR-II Photothermally Enhanced Chemodynamic Therapy.
Topics: Catalysis; Copper; Humans; Nanoparticles; Neoplasms; Quantum Dots; Selenocysteine | 2022 |
Bioluminescence Imaging of Selenocysteine in Vivo with a Highly Sensitive Probe.
Topics: Animals; Benzothiazoles; Female; Humans; Limit of Detection; Luminescence; Luminescent Agents; Luminescent Measurements; MCF-7 Cells; Mice, Inbred BALB C; Mice, Transgenic; Neoplasms; Optical Imaging; Selenocysteine | 2019 |
Selenium detoxification is required for cancer-cell survival.
Topics: Amino Acid Transport System y+; Animals; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Female; Ferroptosis; Humans; Inactivation, Metabolic; Mice; Mice, Nude; Neoplasms; Phospholipid Hydroperoxide Glutathione Peroxidase; Phosphotransferases; Selenium; Selenium Compounds; Selenocysteine; Xenograft Model Antitumor Assays | 2020 |
Poly(Vinylpyrollidone)- and Selenocysteine-Modified Bi
Topics: Bismuth; Humans; Nanoparticles; Neoplasms; Organoselenium Compounds; Polyvinyls; Pyrrolidinones; Radiation-Sensitizing Agents; Selenium Compounds; Selenocysteine; Theranostic Nanomedicine | 2017 |
A reaction-based near-infrared fluorescent probe that can visualize endogenous selenocysteine in vivo in tumor-bearing mice.
Topics: Animals; Drug Stability; Female; Fluorescence; Fluorescent Dyes; Heterografts; Humans; Limit of Detection; Male; MCF-7 Cells; Mice, Nude; Microscopy, Confocal; Microscopy, Fluorescence; Neoplasm Transplantation; Neoplasms; Nitriles; Optical Imaging; Selenocysteine; Ultraviolet Rays | 2018 |
A diterpenoid derivate compound targets selenocysteine of thioredoxin reductases and induces Bax/Bak-independent apoptosis.
Topics: Animals; Antineoplastic Agents; Apoptosis; Catalytic Domain; Diterpenes; Fibroblasts; HCT116 Cells; Humans; Neoplasms; Oxidation-Reduction; Reactive Oxygen Species; Selenocysteine; Selenoproteins; Thioredoxin Reductase 1; Thioredoxin Reductase 2; Thioredoxin-Disulfide Reductase; Thioredoxins | 2013 |
Se-methylselenocysteine offers selective protection against toxicity and potentiates the antitumour activity of anticancer drugs in preclinical animal models.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Cyclophosphamide; Cytoprotection; Female; Humans; Irinotecan; Mice; Mice, Nude; Neoplasms; Organoplatinum Compounds; Oxaliplatin; Rats; Rats, Inbred F344; Selenocysteine; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2014 |
Kynurenine aminotransferase III and glutamine transaminase L are identical enzymes that have cysteine S-conjugate β-lyase activity and can transaminate L-selenomethionine.
Topics: Alkenes; Animals; Carbon-Sulfur Lyases; Cysteine; Histone Deacetylase Inhibitors; Humans; Kinetics; Liver; Mice; Neoplasms; Recombinant Proteins; Selenocysteine; Selenomethionine; Substrate Specificity; Tandem Mass Spectrometry; Transaminases | 2014 |
Evidence for targeting thioredoxin reductases with ferrocenyl quinone methides. A possible molecular basis for the antiproliferative effect of hydroxyferrocifens on cancer cells.
Topics: Animals; Antineoplastic Agents; Cystamine; Ferrous Compounds; Glutathione; Glutathione Reductase; Humans; Indolequinones; Inhibitory Concentration 50; Jurkat Cells; Metallocenes; Neoplasms; Organoselenium Compounds; Rats; Selenocysteine; Thioredoxin-Disulfide Reductase | 2014 |
Alkbh8 Regulates Selenocysteine-Protein Expression to Protect against Reactive Oxygen Species Damage.
Topics: AlkB Homolog 8, tRNA Methyltransferase; Animals; DNA Damage; Fibroblasts; Gene Expression; Gene Expression Regulation; Glutathione Peroxidase; Mice; Mice, Inbred C57BL; Neoplasms; Oxidative Stress; Protein Processing, Post-Translational; Reactive Oxygen Species; RNA, Transfer; Selenocysteine; Thioredoxin-Disulfide Reductase; tRNA Methyltransferases; Uridine | 2015 |
Differential sensitivity of various human tumour-derived cell types to apoptosis by organic derivatives of selenium.
Topics: Adenocarcinoma; Adolescent; Adult; Animals; Anticarcinogenic Agents; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Carcinoma; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Survival; Colonic Neoplasms; Cysteine; Epithelial Cells; Female; Humans; Liver Neoplasms; Male; Melanoma; Middle Aged; Neoplasms; Neuroectodermal Tumors, Primitive, Peripheral; Organoselenium Compounds; Selenium Compounds; Selenocysteine; Selenomethionine; Skin Neoplasms | 2009 |
Differential apoptotic response of human cancer cells to organoselenium compounds.
Topics: Anticarcinogenic Agents; Apoptosis; Blotting, Western; Caspase 3; Caspase 8; Caspase 9; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cysteine; Flow Cytometry; Humans; Neoplasms; Organoselenium Compounds; Selenocysteine; Selenomethionine; Sodium Selenite; Tumor Suppressor Protein p53 | 2010 |
Selenium compounds activate early barriers of tumorigenesis.
Topics: Anticarcinogenic Agents; Antioxidants; Ataxia Telangiectasia Mutated Proteins; Cell Cycle Proteins; Cell Line; Cell Line, Tumor; Cellular Senescence; Cysteine; DNA Damage; DNA Repair; DNA-Binding Proteins; Histones; Humans; Male; Neoplasms; Organoselenium Compounds; Oxidative Stress; Protein Serine-Threonine Kinases; Reactive Oxygen Species; Selenium Compounds; Selenocysteine; Sodium Selenite; Tumor Suppressor Proteins | 2010 |
Uptake, distribution, and speciation of selenoamino acids by human cancer cells: X-ray absorption and fluorescence methods.
Topics: Cell Line, Tumor; Cysteine; Humans; Microscopy, Fluorescence; Neoplasms; Organoselenium Compounds; Selenocysteine; Selenomethionine; X-Ray Absorption Spectroscopy | 2011 |
Susceptibility of the antioxidant selenoenyzmes thioredoxin reductase and glutathione peroxidase to alkylation-mediated inhibition by anticancer acylfulvenes.
Topics: Agaricales; Alkylation; Antineoplastic Agents; Antioxidants; Cell Survival; Cysteine; Enzyme Inhibitors; Glutathione Peroxidase; HeLa Cells; Humans; Neoplasms; Polycyclic Sesquiterpenes; Selenocysteine; Sesquiterpenes; Spiro Compounds; Thioredoxin-Disulfide Reductase | 2011 |
Selenium is a modulator of circadian clock that protects mice from the toxicity of a chemotherapeutic drug via upregulation of the core clock protein, BMAL1.
Topics: Animals; ARNTL Transcription Factors; Cell Line, Tumor; Circadian Clocks; CLOCK Proteins; Cyclophosphamide; Cysteine; DNA-Binding Proteins; Female; Gene Expression Regulation, Neoplastic; HEK293 Cells; Humans; Mice; Mice, Inbred C57BL; Neoplasms; Organoselenium Compounds; Period Circadian Proteins; Promoter Regions, Genetic; RNA Interference; RNA, Small Interfering; Selenium Compounds; Selenocysteine; Transcription Factors; Transcription, Genetic; Transcriptional Activation | 2011 |
Chemically programmed bispecific antibodies that recruit and activate T cells.
Topics: Antibodies, Bispecific; Antibody Specificity; CD3 Complex; Folate Receptor 1; HeLa Cells; Humans; Integrin alpha4beta1; Jurkat Cells; Lymphocyte Activation; Neoplasms; Selenocysteine; T-Lymphocytes | 2012 |
Selective modulation of the therapeutic efficacy of anticancer drugs by selenium containing compounds against human tumor xenografts.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Camptothecin; Carcinoma, Squamous Cell; Cell Line, Tumor; Colonic Neoplasms; Cysteine; Dose-Response Relationship, Drug; Drug Synergism; Female; Humans; Irinotecan; Maximum Tolerated Dose; Mice; Mice, Nude; Neoplasm Transplantation; Neoplasms; Organoselenium Compounds; Radiation-Sensitizing Agents; Selenium; Selenocysteine; Selenomethionine; Time Factors | 2004 |
Efficacy of increasing the therapeutic index of irinotecan, plasma and tissue selenium concentrations is methylselenocysteine dose dependent.
Topics: Administration, Oral; Animals; Bone Marrow; Camptothecin; Cysteine; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Interactions; Female; Humans; Irinotecan; Kidney; Kinetics; Liver; Mice; Mice, Nude; Neoplasms; Organoselenium Compounds; Plasma; Selenium; Selenocysteine | 2007 |